Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients

Citation
Ht. Hassan et al., Factors influencing platelet recovery after autologous transplantation of G-CSF-mobilized peripheral blood stem/progenitor cells following myeloablative therapy in 50 heavily pretreated lymphoma patients, CLIN LAB H, 21(1), 1999, pp. 21-27
Citations number
25
Categorie Soggetti
Hematology
Journal title
CLINICAL AND LABORATORY HAEMATOLOGY
ISSN journal
01419854 → ACNP
Volume
21
Issue
1
Year of publication
1999
Pages
21 - 27
Database
ISI
SICI code
0141-9854(199902)21:1<21:FIPRAA>2.0.ZU;2-F
Abstract
Delayed platelet recovery following autologous PBPCs transplantation after myeloablative therapy remains an unresolved problem in lymphoma patients he avily pretreated with several chemotherapy cycles and/or radiotherapy. In t he present study of 50 lymphoma patients, the factors influencing platelet recovery after myeloablative therapy followed by autologous PBPCs transplan tation were analysed retrospectively. The median age was 42 years (range, 1 5-58). Fourteen patients had HD and 36 had NHL (13 high-grade and 23 low-gr ade); most (80%) had stage III or IV. Twenty-two patients had received radi otherapy to various extents before mobilization. The mean number of previou s chemotherapy cycles was seven (range 3-24) of different regimens (range 1 -4). A median of three leukapheresis procedures (range 1-5) was performed a fter G-CSF mobilization. Single leukapheresis was sufficient in only one pa tient. A significant correlation was found between the BFU-E content of aut ografts and platelet recovery after transplantation. Neither the patient's age and sex nor the stage and grade of lymphoma had any effect on platelet recovery after transplantation. Neither the type of myeloablative therapy u sed or the dose of G-CSF administered after transplantation had any effect on platelet recovery after transplantation. The type of previous chemothera py cycles was a major adverse factor affecting the progenitor cell yield in the autografts. Lymphoma patients previously treated with ASHAP and/or Dex a-BEAM cycles had less progenitor cell yield. The chemotherapeutic agents u sed in previous cycles also had a clear adverse effect on the progenitor ce ll yield in the autografts. Lymphoma patients previously treated with cycle s including cytarabine and/or cisplatin showed significantly less progenito r cell yield and slower platelet recovery after transplantation. All seven patients with delayed platelet recovery had received cytarabine and/or cisp latin in several previous ASHAP and/or Dexa-BEAM cycles. All seven patients had a BFU-E count of less than 1 x 10(5)/kg yield in the autografts.